and morning, Dave Thanks, good everyone.
performance and X nine our months during will the X, of financial Slide in see XXXX. you non-GAAP first and to Moving QX
growth volume of in growth. XX.X%, this X% a on basis key as revenue offset was and foreign Dave As unfavorable sold of international product favorable prices, effect mentioned, partially compared increased versus percent manufacturing by drove efficiencies primarily exchange rates XXXX, decline Gross products QX QX the driven to QX XXXX, as margin quarter and XX revenue of inventory by mix. lower realized a points
our we world. expenses the down XX% and the compared consumers consumer this general marketing increasing to in XXXX, promotion QX increased administrative utilization and in around physicians tactics, as to augment quarter in invested Selling, connection healthcare to meaningfully to direct increases P&L. virtual with Moving
income increased keeps growth. our related As expenses for growth the quarter. quarter, in X% to and our indicative to patients, In COVID-XX and we COVID-XX operating stage minutes, our the R&D development guidance full absolute expenses well, for by year for increased baricitinib neutralizing including year lower in total, as revenue exceeded investments, I'll QX late hospitalized expenses, track assets. development develop compared of efforts expenses as ranges which partially see offset COVID-XX level and fourth by by during X% few the quarter on us a primarily full third XXXX decreased SG&A antibodies discuss expenditures driven Research modest quarter of as our in
going growth revenue the marketing increased forward. customer activation expect to additional We and activity drive
first quarter of the months for operating growth the as During income outpaced of XX.X% nine first revenue was months as revenue by and XXXX. operating expense XXXX, X% the nine percent Operating of XX.X% growth. income increased a third during
As in investment Dave mentioned earlier, our COVID-XX normal outside of business represented our operations. investments therapies
during So margin these XXXX months excluding consistent R&D important programs, XX.X% associated the in our million have operating $XXX expect first our been improvement and nine of continued with guidance, with expenses we QX. would of
QX COVID-XX an to of commercial margin and continue virtual committed sustained likely in was expense income made million where We this environment model to transition We've for a income $XX to we're the Other a impact million $XXX have and our of person expansion in to and of period compared strategy to an allocate resources quarter time. beyond. efficiently in XXXX to hybrid and support in XXXX. expense is executing
innovation This investments and company biopharma part portfolio by strategy. public driven of as income investment of our across primarily quarter's was external private other our gains
this can private regularly highlight, investor we be received bit quite and fluctuate. valuations on line feedback as this As equity a your public We've of volatile item.
due XXXX, group will business our volatility. We our with allow our and to gains in the core we from unpredictable our investments non-GAAP beginning non-GAAP better this believe exclude results for peer remove with operations, will measures. losses align or So comparisons equity easier
mix year, last versus tax with an XX.X%, increase lower rate by tax compared our the the XXX quarter, this jurisdictions of net the tax points and same same earnings This of year. last higher in quarter driven benefits quarter was discrete basis quarter
the comfortable While tax with roughly we corporate line, structure. to per XX% At US under bottom current tax variability, X%. the XX% increased share expect remain earnings we of expectations some long-term rate quarterly
effect Worldwide volume of months revenue. increased XX%. and was X share nine earnings first revenue X% of XX, as X% the per partially Slide volume describe During increased the growth On and by rates of XXXX, offset during price, we price. QX on
on impact revenue had positive Foreign growth. X% exchange rates
to impact impacting X% alliance. and our driven on impact changes estimates BI X%, for drag maintain discounts, points X% During modest Price quarter Trulicity. nine our revenue the of XXXX, Verzenio, In revenue worldwide offset to the and growth the Tradjenta grew X% increased X% a partially net by to across the growth. from portfolio line and of most access, list notably point of you volume the drag to X% was or China. rebates XXXX. exclude increases. by partially impact due restructuring a Taltz expectations, of price price revenue on X% by due the Trulicity, US was of of X% were compared U.S. for strong Alimta in to by months the commercial rebates Forteo was with was increased if growth growth first and grew Tyvyt competition Volume the of third led XX%. on offset
D not detailed performance we for on would of gap. in liability increased entry price pricing do dynamics Part assumed coverage due impact provide coverage threshold the short-term to products, our the and some we shift healthcare quarters, gap utilization QX. by commentary COVID-XX In deferral typically for on caused Trulicity individual discuss to additional will the While of prior the the I in impact of year into later
However similar years. anticipate Part informed to from now patterns customers, prior invoices D by recent we our
updated drag impact in rate. Trulicity’s this estimates double a to So meaningful a results resulted and growth on led that QX on digit
for Our estimated unchanged. impact gap year largely full coverage though the is
the the third of QX months versus the high digits XXXX. one-time and Excluding double XXXX nine low quarter by digits the single for Trulicity’s of in declined price impact first adjustments,
decline We expect toward digit Trulicity Trulicity. guided for the a for for decline high single year, price year. mid-single Last price we full digit a
driven segments. in to rebated be our growth modest increases offset We highly increasing list maintain price rebates by expected partially rates excellent this modest by to and more access,
XX, on of impact XXXX growth XXXX. and the next On has and As segment segment of Trulicity price higher been negative we than to impact growth mix. Trulicity XXXX expected, Slide due unfolded, we the has primarily on rate show in
While list mid-single our has headwinds, rebate rates rate increases is digits the with or lower, expectations. was pricing consistent impact a modest been and which of increased price net
mix. segment to Moving
faster similar Medicaid, commercial the segments other states, QX of segments. a we market net segment. market through This XXXX. through segment in in and than Medicaid pull We access currently share months Within was price depressed expansion in commercial deliver by the While continues our first faster. to to X primarily experienced Medicaid in driven nine and lesser GLP-X. grown of XXXX Trulicity and be have exceeded X% lower across This by this in percentage and and robust XX% points year. segments anticipated has in reported with changes wins Trulicity’s growth market all significantly lives total share exited XXXX formulary of the points the approximately to growth growth, expectations key of leading a percentage Medicare of continued continues extent sector
in XXXX GLP-X at in with gained since other share consistent quarter the XX% worth volume as It's and a low expect growth additional class less GLP-Xs Medicare, segments still significant Medicaid opportunity suggests in continue. is and penetration across and all market volume we to are growth immature for these used and of finished that X.X market. share growth, utilization segments QX of of Medicaid we disproportionate points percentage in segments. However, noting a
gains business, volume have they business than realized do diabetes. Trulicity lower help more commercial are with a living price these profitable Although, able represent people and our
net declines performance with and high So price declines in Trulicity faster we price project unit single-digit XXXX. continued modest total across lower to access into strong segments growth in result continued expect all in segments, XXXX, and as we price
note to segment decline, also GLP-Xs I which faster shows this as up for price net growth growth, that However, would higher the prescription contributes as overall well.
of mid into trends Our outlook XXXX. in we well decline to million the single-digit XXXX moving remains for single-digit on XXXX. expect as as pricing $XXX in US This US price in segment for impact noted continue from full as declines as impact $XXX and a XXXX, affected increased price unemployment million unchanged well includes, quarter, approximately to we mid as the modest outlook mix, total year last
Okay.
offset Alimta of help by strong These offset to by recently cancer growth, in constant products to in in ad grew by concessions oncology was Alimta In substantially Olumiant, We're Taltz, court a were partially growth important to volume China, regulatory positively Humalog, the Outside Jardiance excited Verzenio Humulin Revenue and offset and programs price. ordered in by and Olumiant patients X% increased significant Europe. on growth, drive currency the Trulicity, in partially was well the Cialis sponsored offset of from Jardiance X% Revenue portfolio and well have for to by in Verzenio XXXX. constant by which look and currency, volume. in increased by good victory Trulicity, and the continue Cialis, currency, performance Verzenio. partially world that products, key as market, Japan, to launched in as partially due our Forteo. XX% grew growth rest volume competition volume impacted volume programs. from decreases from China, by our Volume Moving revenue Trulicity, strong revenue business grew receiving government is constant and Japan benefited appeal Olumiant coming oncology XX%, volume from grew our of increased inclusion price Forteo, months. sale the growth generics partially effective uptick. decreased our driven and In currency X% injunction against China’s constant as Germany China entered Trulicity, by had patent Tyvyt driven medicines. access Taltz, of about and government one-time pricing offset in X% a the of volume revenue XX% March forward action for from mandated these that as momentum increased growth
contributed growth our points products the lower in Ingelheim year. Slide the of the our a approximately to our products As XX, continue In XX% royalties nearly billion growth. revenue this revenue. volume our volume quarter. system term, months impact worldwide total, new with are Slide growth. making XX% was year-to-date growth of products. $X drive over see starts starts the COVID-XX. These In Trajenta of shown strong well we XXXX volume last products experienced offset and as highlights an generated The recover competition long reduced reopened new this product up growth XX volume XX have Forteo, contributions of post-LOE around mix patient Though first these key patient key reduced key nine that key in well-positioned from trend on the Boehringer We to to performance we of brands of QX the percentage our key our end drive alliance the medicines quarter, for in growth QX, announced partially from of health utilization continue by as pleased delivered were impressive encouraged as nearly see strong to world. to due products off troughs restructuring
XX, have on most recorded remain an update classes below baselines. On Slide to different XX% classes we While XX% pre-COVID allocation. capital different provide rates,
number nine capital including tax of stage the we expenditures a development, invested During in business in early addition of combination future months of investment XXXX, and through billion after agreements. nearly of a $X to lebrikizumab drive R&D, the our growth first
at ability debt In returned have rates. attractive share We the well via dividend. and capitalized $X.X the repurchase over we to remain market billion and access to addition, shareholders
travel first by do We expect best-in-class we to impacts or And long-term affect COVID enhance efforts. pipeline to not our our anticipate market uncertainty growth assets. to continue acquiring regarding or
to utilize on XX, best and to our despite based in due promotion. spend time. visits improve of US; returning financial estimates changes supporting to will unemployment continue you'll utilization in continue patient increased segment interactions, our in-person investments modest; in Slide the will New include: in seen XXXX historical updated mix and, additional digital US constitute this affordability Moving mix to guidance and a telehealth the be at Healthcare or this and prescriptions headwinds outbreaks; increased patient to COVID-XX guidance, in promotional of customer program levels Pricing activity trends QX, will assumptions positive continue person as will direct-to-consumer Key find doctors is from the advertising,
of any priority economic around of patients healthcare world, While impact we ways COVID-XX find to the be the pace remains most resulting activity believe and uncertainty will a waves regarding access resurgent recovery do continue to that will healthcare. on and
current At year-over-year our X% end up from So we're these third but maintaining moderate in range. is course Achieving we price quarter our based higher to QX point. the growth which limited volume antibody, our by a of from not believe likely would the of trends on be while sales U.S. end current rate, in growth of step some our supported expectations the COVID of revenue low is the requires range and range, sales assumptions, full-year this X%, more impacts possible which at the certain
income Moving the statement. down
as a non-GAAP basis. a margin revenue and of on is Our GAAP gross unchanged percent
We selling billion and range for our $X $X.X are to marketing, billion. to expenses administrative narrowing
XX% these noting percent margin our push treatment of $X.X million are non-GAAP continue these these narrowing operating end costs, expenses expect investments with of We're Lilly research believe range global to with year COVID-XX We full $X.X of approximately to our the us high and $XXX to likely any revenue of XX%. We to help for revenue our to fund COVID-XX billion, substantial to are of programs. self Inclusive investments treatments an the excludes billion the as for that of combat a in range approximately goal as investment pandemic. development in our critical associated them. income we and operating
income, the and equity $XXX income in to million of on be in portfolio quarter. post for and these our investments our decision for operating reflecting operating of to launch, seen the third continue margin, to our range pressure to do income. these We're near-term expense they be $XXX gains we In other put society. company to therapies the our additional While million updating accretive right expect
previously As is this capital mentioned, of markets. subject to number volatility the
our to effective per approximately non-GAAP XX%. Turning a We're GAAP on Earnings guidance and taxes. are at share non-GAAP unchanged basis. maintaining tax rate
GAAP is $X.XX. the range of to be expected $X.XX EPS Our in to
pandemic. QX we're pretty with of noted our are the why $X.XX EPS we totals outlook proud the as We're the making in on despite a business range, exit the on the year confident head and our will were We impact which to maintaining of continue highly into revenue challenges. investments revenue is QX and the quarter. be exit our delivering broad for COVID-XX current to I our dependent underlying the sales, range QX, ability positioned help As momentum COVID and strong we overcome with well combat to COVID-XX productivity, we'll growth of in fourth strength we Based for XXXX. believe underlying
data So a an call and to key treatments to in develop provide turn our disclosures for Dan I'll now of overall the summary QX over COVID-XX, pipeline on efforts an to update update. ongoing
